Indian Phase III Trial Shows Carboplatin Benefits Premenopausal Triple-Negative Breast Cancer Patients
Key Insights
A phase III trial from Tata Memorial Centre found that adding carboplatin to neoadjuvant chemotherapy significantly improved overall survival in triple-negative breast cancer (search) patients, with a 5-year rate of 74.4% versus 66.8% in controls.
The survival benefit was exclusively observed in premenopausal patients, who showed both improved event-free survival (75.0% vs 59.6%) and overall survival (78.2% vs 64.6%) at 5 years.
Postmenopausal patients showed no benefit from carboplatin addition, suggesting biological differences between age groups that may guide personalized treatment approaches.
A landmark phase III trial from India's Tata Memorial Centre has demonstrated that adding carboplatin to standard neoadjuvant chemotherapy significantly improves overall survival in triple-negative breast cancer (search) (TNBC (search)) patients, with benefits concentrated exclusively in premenopausal women. The study, published in the Journal of Clinical Oncology, represents one of the largest single-center trials evaluating platinum-based therapy in this aggressive breast cancer subtype.
Study Design and Patient Population
The open-label randomized trial enrolled 717 patients with stage II-III TNBC (search) between April 2010 and January 2020. Patients were randomly assigned to receive either weekly paclitaxel (100 mg/m²) plus carboplatin (AUC 2) for 8 weeks followed by anthracycline (search) plus cyclophosphamide, or the same regimen without carboplatin. The primary endpoint was event-free survival, with secondary endpoints including overall survival, pathologic complete response (pCR), and toxicity.
With a median follow-up of 67.6 months, the study provides robust long-term survival data that has been eagerly awaited by the oncology community.
Overall Survival Benefit Despite Missing Primary Endpoint
While the trial did not meet its primary endpoint of improved event-free survival in the overall population, it demonstrated a significant overall survival advantage. The 5-year overall survival rate was 74.4% in the carboplatin group versus 66.8% in the control group (HR = 0.74, 95% CI = 0.57-0.97, P = .029).
Event-free survival showed a numerical improvement that approached statistical significance, with 5-year rates of 70.7% versus 64.1% (HR = 0.80, 95% CI = 0.62-1.03, P = .081). The carboplatin group also achieved significantly higher pathologic complete response rates (54.5% vs 40.3%, P < 0.001).
Striking Age-Related Differences in Treatment Response
The most compelling finding emerged from the preplanned subgroup analysis by menopausal status. Among premenopausal patients, who comprised 58% of the study population, carboplatin addition produced dramatic improvements in both survival endpoints.
Premenopausal patients in the carboplatin group achieved 5-year event-free survival of 75.0% versus 59.6% in controls (HR = 0.61, 95% CI = 0.43-0.84, P = .003). The overall survival benefit was even more pronounced, with 5-year rates of 78.2% versus 64.6% (HR = 0.57, 95% CI = 0.40-0.82, P = .002).
In stark contrast, postmenopausal patients derived no benefit from carboplatin addition, with no differences observed in either event-free survival (HR = 1.19, P = .386) or overall survival (HR = 1.06, P = .772). Statistical testing confirmed significant interactions between treatment and menopausal status for both survival endpoints.
Biological Rationale for Age-Related Response
The differential response patterns align with emerging understanding of TNBC (search) biology across age groups. Premenopausal TNBC typically exhibits more aggressive, immune-rich characteristics with higher tumor-infiltrating lymphocyte counts, more basal-like features, and increased homologous recombination deficiency. These biological features make younger patients' tumors more susceptible to DNA (search)-damaging agents like platinum compounds.
Conversely, postmenopausal TNBC (search) often shifts toward luminal androgen receptor-positive, lower-proliferation biology with fewer immune cells and intact DNA (search) repair mechanisms, rendering these tumors less responsive to platinum-based therapy.
Safety Profile and Treatment Completion
The addition of carboplatin was generally well-tolerated, with 90% of patients completing their planned treatment. The primary safety concern was increased grade ≥3 myelosuppression in the carboplatin group, while non-hematologic toxicities remained comparable between arms.
Clinical Implications and Global Context
The findings have particular relevance for healthcare systems where immunotherapy access remains limited due to cost or availability constraints. In such settings, the weekly paclitaxel plus carboplatin followed by anthracycline (search) sequence provides a robust, curative option specifically for premenopausal TNBC (search) patients.
The study's results also emphasize the importance of biology-driven treatment personalization rather than uniform treatment intensification across all patient populations. The clear age-related differential response suggests that menopausal status should be considered when making treatment decisions about platinum incorporation in TNBC (search).
This research represents a significant contribution from Indian oncology to the global evidence base and demonstrates how well-designed trials in resource-limited settings can generate practice-changing data for cancer care worldwide.